argenx SE (ARGX)
605.92
+9.18
(+1.54%)
USD |
NASDAQ |
Nov 22, 16:00
597.01
-8.91
(-1.47%)
Pre-Market: 20:00
argenx Profit Margin (Quarterly): 15.95% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 15.95% |
June 30, 2024 | 6.09% |
March 31, 2024 | -15.36% |
December 31, 2023 | -24.38% |
September 30, 2023 | -22.03% |
June 30, 2023 | -34.88% |
March 31, 2023 | -13.17% |
December 31, 2022 | -22.17% |
September 30, 2022 | -170.3% |
June 30, 2022 | -277.6% |
March 31, 2022 | -970.4% |
December 31, 2021 | -913.9% |
September 30, 2021 | -27.26K% |
June 30, 2021 | 33.18% |
March 31, 2021 | -25.57% |
December 31, 2019 | -491.4% |
September 30, 2019 | -329.8% |
June 30, 2019 | -688.0% |
March 31, 2019 | 18.51% |
December 31, 2018 | -2.38K% |
September 30, 2018 | -782.6% |
June 30, 2018 | -10.43% |
Date | Value |
---|---|
March 31, 2018 | -317.0% |
December 31, 2017 | -139.1% |
September 30, 2017 | -129.5% |
June 30, 2017 | -2.09% |
March 31, 2017 | -126.3% |
December 31, 2016 | -227.9% |
September 30, 2016 | -107.5% |
June 30, 2016 | -127.4% |
March 31, 2016 | -134.0% |
December 31, 2015 | -286.1% |
September 30, 2015 | -134.9% |
June 30, 2015 | -269.1% |
March 31, 2015 | -246.2% |
December 31, 2014 | -256.2% |
September 30, 2014 | -86.88% |
June 30, 2014 | -1.19K% |
March 31, 2014 | -546.0% |
December 31, 2013 | -223.1% |
September 30, 2013 | -6.14% |
June 30, 2013 | -746.2% |
March 31, 2013 | -414.4% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-27.26K%
Minimum
Sep 2021
33.18%
Maximum
Jun 2021
-1.89K%
Average
-24.97%
Median
Profit Margin (Quarterly) Benchmarks
Biodexa Pharmaceuticals PLC | -- |
uniQure NV | -1.94K% |
ProQR Therapeutics NV | -211.0% |
Akari Therapeutics PLC | -- |
Merus NV | -848.7% |